Načítá se...
At baseline patients treated with esketamine have higher burden of disease than other patients with treatment resistant depression: Learnings from a population based study
INTRODUCTION: It is critical to assess who is being treated with a new marketed drug like esketamine to understand how it is used in the real‐world setting and the effects of the medication. METHODS: Retrospective analysis using two large U.S. health care databases that included commercially insured...
Uloženo v:
| Vydáno v: | Depress Anxiety |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley and Sons Inc.
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8248018/ https://ncbi.nlm.nih.gov/pubmed/33475213 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/da.23138 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|